Gao et al. have provided evidence to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1 [72]. The gene discussed is HMOX1; the disease is nonpapillary renal cell carcinoma.